Analysis of the relationship between pharmacological inhibition of cyclic nucleotide phosphodiesterase and relaxation of canine tracheal smooth muscle.
D015056:1-Methyl-3-isobutylxanthine / Q000494:pharmacology; D015105:3',5'-Cyclic-AMP Phosphodiesterases / Q000037:antagonists & inhibitors*; D015106:3',5'-Cyclic-GMP Phosphodiesterases / Q000037:antagonists & inhibitors*; D000403:Airway Resistance / Q000187:drug effects*; D000818:Animals; D002110:Caffeine / Q000494:pharmacology; D004285:Dogs; D004974:Etazolate / Q000494:pharmacology; D005260:Female; D066298:In Vitro Techniques; D009119:Muscle Contraction / Q000187:drug effects*; D009126:Muscle Relaxation / Q000187:drug effects*; D009130:Muscle, Smooth / Q000187:drug effects*; D010726:Phosphodiesterase Inhibitors / Q000494:pharmacology; D011719:Pyrazines / Q000494:pharmacology; D013806:Theophylline / Q000494:pharmacology; D014132:Trachea / Q000187:drug effects / Q000201:enzymology; D014230:Triazoles / Q000494:pharmacology
D010726:Phosphodiesterase Inhibitors; D011719:Pyrazines; D014230:Triazoles; D002110:Caffeine; D013806:Theophylline; D015105:3',5'-Cyclic-AMP Phosphodiesterases; D015106:3',5'-Cyclic-GMP Phosphodiesterases; D004974:Etazolate; D015056:1-Methyl-3-isobutylxanthine